Anita H. Clayton, MD, joins Scientific Advisory Board TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum…


Previous articleCaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
Next articleHamilton Morris joins COMPASS Pathways to research new psychedelic compounds